-
ATRX (RBT-ATRX)
ATRX (RBT-ATRX)
- 中文名称：
- ATRX (RBT-ATRX)
- 英文名称：
- ATRX (RBT-ATRX)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59355
- 规格：
- 3 mL (RTU)|0.1 mL (Concentrate)|7 mL (RTU)|0.5 mL (Concentrate)|15 mL (RTU)
- 保存建议：
- Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)
- 货期：
- 6-8周
- 来源宿主：
- Rabbit
- 反应种属：
- Human
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:IgG
克隆号:[RBT-ATRX]
特异性:N/A
纯度:N/A
形式：Paraffin, Frozen
ATRX is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
浓度：N/A
- 说明书：
alpha-thalassemia/mental retardation syndrome X-linked (ATRX) gene is located on chromosome Xq21.1. ATRX is involved in many fundamental cellular processes such as transcription, replication, DNA repair and recombination. Germline mutations of ATRX have been found to cause the complex genetic disorder called Alpha-Thalassemia mental retardation syndrome. Somatic mutations, deletions, and altered ATRX expression levels were found to be prevalent in several cancer types. A study reported the loss of ATRX expression was found to be a prognostic marker for chromosome instability in pancreatic neuroendocrine tumors. There is also evidence that highlights the role of ATRX as a biomarker in breast cancer in which ATRX expression was significantly associated with tumor grade.
Mutation/loss of ATRX antibody expression has been described in anaplastic gliomas. A study explored the role of ATRX status in the molecular classification of anaplastic gliomas and its impact on survival. Loss of ATRX antibody expression was detected in 45 % of anaplastic astrocytomas (AA), 27 % of anaplastic oligoastrocytomas (AOA) and 10 % of anaplastic oligodendrogliomas (AO). Survival analysis showed a marked separation of IDH mutant astrocytic tumors into two groups based on ATRX status: tumors with ATRX loss had a significantly better prognosis. Another recent study analyzed the use of ATRX, IDH and 1p/19q codeletion in a series of astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas and presented an algorithm based on stepwise analysis with initial immunohistochemistry for ATRX and IDH1-R132H followed by 1p/19q analysis, then by IDH sequencing, which reduces the number of molecular analyses and has a far better association with patient outcome.
